iBio, a New York-based plant-based biotechnology company, has completed the product development capacity expansion of its subsidiary, iBio CMO, for production of pharmaceutical proteins in hydroponically-grown green plants. iBio is currently developing several vaccine and therapeutic candidates and is expanding to the monoclonal antibody product category.

This expansion enables iBio to conduct concurrent product development work ffrom laboratory-level feasibility and testing through cGMP production of active pharmaceutical ingredients for toxicology studies and Phase 1 human clinical trials.

Source: iBio